Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Eribulin (Primary) ; Gemcitabine (Primary) ; Ipatasertib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms PATHFINDER

    • Most Recent Events

    • 04 Jun 2024 Results (At data cutoff (10th November 2023) assessing toxicity and efficacy of IPA with non-taxane CT in aTNBC pts presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2024 According to a MEDSIR media release, company today announced results from this clinical trial during the 2024 ASCO Annual Meeting.
    • 05 Apr 2024 This study has been Completed in Portugal According to European Clinical Trials Database Record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top